Exenatide
Trovati 10 articoli
- Management of patients with diabetes mellitus
- The treatment of patients with diabetes mellitus should be based, wherever possible, on the results of studies of substantial size and duration that measure outcomes that are meaningful to patients. While treatment of hypertension and hyperlipidaemia reduce progression of micro-vascular disease,... (Leggi Articolo)
- Diabetes: promising advances in islet cell transplants
- Researchers at University of Illinois at Chicago ( UIC ) have modified the procedure for islet cell transplantation and achieved insulin independence in diabetes patients with fewer but better-functioning pancreatic islet cells. The study results are published in the American Journal of Transp... (Leggi Articolo)
- Cases of hemorrhagic or necrotizing pancreatitis in patients taking Byetta
- Since October 2007, FDA ( Food and Drug Administration ) has received reports of 6 cases of hemorrhagic or necrotizing pancreatitis in patients taking Byetta ( Exenatide ). Byetta is a medicine given by subcutaneous injection to help treat adults with type 2 diabetes. Of the 6 cases of hem... (Leggi Articolo)
- Byetta: sustained improvements in blood glucose control and progressive weight loss after two years
- A two-year study has shown that Exenatide ( Byetta ) injection sustained improvements in blood glucose control and reduced body weight in people with type 2 diabetes who previously did not achieve adequate control of their blood sugar on common oral medications. After two years of treatment, p... (Leggi Articolo)
- FDA has approved Byetta in patients with type 2 diabetes
- FDA ( Food and Drug Administration ) has approved Exenatide ( Byetta ), also known as synthetic exendin-4, injection as adjunctive therapy to improve blood sugar control in patients with type 2 diabetes who have not achieved adequate control on Metformin and/or a sulfonylurea. Exenatide is the... (Leggi Articolo)
- Diabetes mellitus: once weekly Byetta LAR improves glucose control
- The study was designed to assess the safety, tolerability and pharmacokinetics of Exenatide ( Byetta ) LAR (long-acting release ) given once a week. After 15 weeks, both doses of Exenatide LAR were well tolerated and expected therapeutic blood levels of Exenatide were achieved. Dose-dependent... (Leggi Articolo)
- Byetta reduces HbA1c in patients poorly controlled on Metformin
- Exenatide ( Byetta ) reduced HbA1c with no weight gain and no increased incidence of hypoglycemia in patients with type 2 diabetes failing to achieve glycemic control with Metformin. Exenatide is the first in a new class of drugs for the treatment of type 2 diabetes called incretin mimetics, a... (Leggi Articolo)
- Exenatide improves blood glucose as effectively as Insulin Glargine
- Results from a study indicate that Exenatide injection ( Byetta ) improves blood glucose levels as effectively as Insulin Glargine ( Lantus ) for patients with type 2 diabetes failing to achieve acceptable blood gluocse control on both Metformin and a sulfonylurea, two common oral diabetes medica... (Leggi Articolo)
- Type 2 diabetes: Galvus improves function of pancreatic islets and glycemic control
- Research suggests that the investigational drug Vildagliptin ( Galvus ) improves the function of pancreatic islets in both animals and humans. Improved pancreatic islet function is a long-standing goal for the treatment of type 2 diabetes. Researchers also reported that Vildagliptin, a novel ... (Leggi Articolo)
- Diabetes mellitus type 2: Exenatide shows sustained improvements in glucose control and progressive weight reduction
- Results from a study indicating that Exenatide ( Byetta ) injection showed sustained improvements in blood glucose control and progressive weight reduction through a year and a half of therapy for people with type 2 diabetes failing to achieve acceptable blood glucose control on Metformin and/or ... (Leggi Articolo)
